Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-12-18
2007-12-18
Schultz, J. Douglas (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024310, C536S024330, C536S024500
Reexamination Certificate
active
08679437
ABSTRACT:
The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crk1 nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.
REFERENCES:
patent: 4229360 (1980-10-01), Schneider et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4837028 (1989-06-01), Allen
patent: 4904582 (1990-02-01), Tullis
patent: 4920016 (1990-04-01), Allen et al.
patent: 5094785 (1992-03-01), Law et al.
patent: 5188897 (1993-02-01), Suhadolnik et al.
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5225326 (1993-07-01), Bresser et al.
patent: 5279833 (1994-01-01), Rose
patent: 5376646 (1994-12-01), Pittrof et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5510239 (1996-04-01), Baracchini et al.
patent: 5527538 (1996-06-01), Baldeschwieler
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5661018 (1997-08-01), Ashley et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5696248 (1997-12-01), Peyman et al.
patent: 5705385 (1998-01-01), Bally et al.
patent: 5734033 (1998-03-01), Reed
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5750669 (1998-05-01), Rosch et al.
patent: 5831048 (1998-11-01), Schwighoffer et al.
patent: 5831066 (1998-11-01), Reed
patent: 5874224 (1999-02-01), Bandman et al.
patent: 5891714 (1999-04-01), Ashley et al.
patent: 5908635 (1999-06-01), Thierry
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 6015886 (2000-01-01), Dale et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6040181 (2000-03-01), Reed
patent: 6096720 (2000-08-01), Love et al.
patent: 6110490 (2000-08-01), Thierry
patent: 6120794 (2000-09-01), Liu et al.
patent: 6120798 (2000-09-01), Allen et al.
patent: 6126965 (2000-10-01), Kasid et al.
patent: 6136965 (2000-10-01), Bruice et al.
patent: 6211162 (2001-04-01), Dale et al.
patent: 6211349 (2001-04-01), Dale et al.
patent: 6277832 (2001-08-01), Sugiyama et al.
patent: 6277981 (2001-08-01), Tu et al.
patent: 6291668 (2001-09-01), Ziegler et al.
patent: 6326487 (2001-12-01), Peyman et al.
patent: 2113494 (1995-07-01), None
patent: WO 88/04924 (1988-07-01), None
patent: WO 88/042924 (1988-07-01), None
patent: WO 95/09236 (1995-04-01), None
patent: WO 95/31545 (1995-11-01), None
patent: WO 97/20573 (1997-06-01), None
patent: WO 00/40595 (2000-07-01), None
patent: WO 02/17852 (2002-03-01), None
Westermann et al., Inhibition of expression of SV-40 virus large T-antigen by antisense oligodeoxyribonucleotides, Biomed. Biochim. Acta, vol. 48(1), pp. 85-93, 1989.
Mulligan, The basic science of gene therapy, Science, vol. 260, pp. 926-932, May 1993.
James, Towards gene inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozyme, Antiviral Chemistry and Chemotherapy, vol. 2(4), pp. 191-214, 1991.
Uhlmann et al., Antisense oligonucleotides: a new therapeutic principle, Chemical Reviews, vol. 90(4), pp. 543-584.
Weiss, Upping the antisense ante, scientist bet on profits from reverse genetics, Science News, vol. 139, pp. 108-109, Feb. 1991.
Tseng et al., Antisense oligonucleotide technology in the development of cancer therapeutics, Cancer Gene Therapy, vol. 1(1), pp. 65-71, Mar. 1994.
Lowenstein et al., The SH2 and SH3 domain containing protein Grb2 links receptor tyrosine kinases to ras signaling, Cell, vol. 70, pp. 431-442, Aug. 1992.
Gewirtz et al., Facilitating oligonucleotide delivery: Helping antisense deliver on its promise, Proc. Natl. Acad. Sci., vol. 93, pp. 3161-3163, Apr. 1996.
Ten Hoeve et al., Isolation and chromosomal localization of CRKL, a human crk-like gene, Oncogene, vol. 8, pp. 2409-2414, 1993.
Weintraub, H. Antisense RNA and DNA. Scientific American 1990:40-46.
Baichwal and Sugden, “Vectors for Gene Transfer Derived from Animal DNA Viruses: Transient and Stable Expression of Transferred Genes,”In: Gene Transfer,Kucherlapati (Ed.), New York: Plenum Press, 1986.
Bangham et al., “Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids,”J. Mol. Biol.,13:238-252, 1965.
Bedi et al., “Inhibition of Apoptosis by BCR-ABL in Chronic Myeloid Leukemia,”Blood,38(9):2038-2044, 1994.
Benvenisty and Reshef, “Direct Introduction of Genes into Rats and Expression of the Genes,”Proc. Natl. Acad. Sci. USA,83:9551-9555, 1986.
Chang et al., “Foreign Gene Delivery and Expression in Hepatocytes Using a Hepatitis B Virus Vector,”Hepatology,14(4, Pt. 2):124A, 1991.
Chen and Okayama, “High-Efficiency Transformation of Mammalian Cells by Plasmid DNA,”Mol. Cell. Biol.,7(8): 2745-2752, 1987.
Coffin, “Retroviridae and their Replication,”In : Virology,2nd Edition, Fields et al. (Eds.), New York: Raven Press, pp. 1437-1500, 1990.
Coupar et al., “A General Method for theConstruction of Recombinant Vaccinia Viruses Expressing Multiple Foreign Genes,”Gene,68:1-10,1988.
Dubensky et al., “Direct Transfection of Viral and Plasmid DNA into the Liver or Spleen of Mice,”Proc. Natl. Acad. Sci. USA,81:7529-7533, 1984.
Fechheimer et al., “Transfection of Mammalian Cells with Plasmid DNA by Scrape Loading and Sonication Loading,”Proc. Natl. Acad. Sci., USA,84:8463-8467, 1987.
Fraley et al., “Entrapment of a Bacterial Plasmid in Phospholipid Vesicles: Ptoential for Gene Transfer,”Proc. Natl. Acad. Sci., USA,76(7):3348-3352,1979.
Friedmann, “Progress Toward Human Gene Therapy,”Science,244:1275-1281, 1989.
Ghosh and Bachhawat, “Targeting of Liposomes to Hepatocytes,”In: Liver Diseases, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands,Wu and Wu (Eds.), New York: Marcel Dekker, pp. 87-103, 1991.
Gopal, “Gene Transfer Method for Transient Gene Expression, Stable Transformation, and Cotransformation of Suspension Cell Cultures,”Mol. Cell. Biol.,5(5):1188-1190, 1985.
Graham and van der Eb, “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,”Virology,52:456-467, 1973.
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,”J. Gen. Virol,36:59-72, 1977.
Gregoriadis, “Liposomes,”In: Drug Carriers in Biology and Medicine,Gregoriadis (Ed.), New York: Academic Press, pp. 287-341, 1979.
Grunhaus and Horwitz, “Adenoviruses as Cloning Vectors,”Seminar in Virology,3:237-252, 1992.
Harland and Weintraub, “Translation of mRNA Injected into Xenopus Oocytes is Specifically Inhibited by Antisense RNA,”J Cell Biology,101:1094-1099, 1985.
Hermonat and Muzyczka, “Use of Adeno-Associated Virus as a Mammalian DNA Cloning Vector: Transduction of Neomycin Resistance into Mammalian Tissue Culture Cells,”Proc. Natl. Acad. Sci., USA,81:6466-6470, 1984.
Horwich et al., “Synthesis of Hepadnavirus Particles that Contain Relication-Defective Duck Hepatitis B Virus Genomes in Cultured HuH7 Cells,”J Virology,64(2):642-650, 1990.
Kaneda et al., “Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver,”Science,243:375-378, 1989.
Kato et al., “Expression of Hepatitis B Virus Surface Antigen in adult Rat Liver,”J. Biol. Chem.,266(6):3361-3364, 1991.
Klein et al., “High-Velocity Microprojectiles for Delivering Nucleic Acids into Living Cells,”Nature,327:70-73, 1987.
Lowenstein et al., “The SH2 and SH3 Domain-Containing Protein GRB2 Links Receptor Tyrosine Kinases to ras Signaling,”Cell,70:431-442, 1992.
Mann et al., “Construction ofa Retrovirus Packaging Mutant
Arlinghaus Ralph B.
Lopez-Berestein Gabriel
Tari Ana M
Board of Regents , The University of Texas System
Chong Kimberly
Fulbright & Jaworski L.L.P.
Schultz J. Douglas
LandOfFree
Inhibition of chronic myelogenous leukemic cell growth by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of chronic myelogenous leukemic cell growth by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of chronic myelogenous leukemic cell growth by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3852606